Deals
Shanghai Pharma Eyes Acquisitions After Cardinal China Deal
- State-owned firm targets specialty drugs, branded generics
- Shanghai Pharma scouts for deals in U.S., Germany, Switzerland
This article is for subscribers only.
Shanghai Pharmaceuticals Holding Co. is exploring further acquisitions after it beat out global buyout firms to buy Cardinal Health Inc.’s Chinese distribution business in a $1.2 billion deal.
The state-owned drugmaker is scouting for purchases of pharmaceutical manufacturing assets overseas, David Liu, head of mergers and acquisitions at Shanghai Pharma, said in an interview Wednesday. Shanghai Pharma is interested in deals related to specialty drugs, including treatments for cancer and cardiovascular conditions, as well as branded generics, Liu said.